跳至主要内容
临床试验/NCT01166087
NCT01166087已完成1 期

A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules 90 mg of Dr. Reddy's and Prozac®Weekly 90 mg Delayed Release Capsules of Eli Lilly and Company, USA in Healthy Adult Human Subjects Under Fed Conditions.

Dr. Reddy's Laboratories Limited1 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2006年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
54
试验地点
1
主要终点
Bioequivalence based on Cmax and AUC parameters

研究概览

简要总结

The purpose of this study is to asses the bioequivalence study of Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg and Prozac ® weekly under fed conditions.

详细描述

A randomized, open label, two treatment, two period, two sequence, single dose, crossover bioequivalence study of Fluoxetine Hydrochloride Delayed-Release capsules 90 mg of Dr. Reddy's laboratories limited, Generics, India and Prozac®weekly 90 mg delayed release capsules of Eli Lilly and company, USA in healthy adult human subjects under fed conditions.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy human subjects between 18-50 years of age (inclusive), weighing as per the standard height and weight chart of Life Insurance Corporation of India (11 Underweight and Overweight Min. & Max. Chart).
  • Subjects who have no evidence of underlying disease during screening medical history and whose physical examination is performed within 21 days prior to commencement of the study.
  • Subjects whose screening laboratory values are within normal limits or considered by the physician/Principal Investigator to be of no clinical significance.
  • Informed consent given in written form according to section 11.3 of the protocol.
  • Female Subjects
  • of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies,diaphragm, intrauterine device, or abstinence.
  • postmenopausal for at least I year.
  • surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject)

排除标准

  • Cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease.
  • Alcohol dependence, Alcohol abuse, i.e., regular use of more than 2 units of alcohol or 10 units per week or a history of alcoholism (one unit of alcohol equals 1/2 1 of beer 200 ml wine or 50 ml (of spirits) within last 6 months or recovered alcoholics , or drug abuse within past 1 year.
  • Moderate to heavy smoking (> 10 cigarettes/day) or consumption of tobacco products.
  • History of difficulty in swallowing capsules.
  • Clinically significant illness within 4 weeks before the start of the study.
  • Asthma, urticaria or other allergic type reactions after taking any medication.
  • Positive urine drug screening, Human Immunodeficiency Virus, Hepatitis B & C tests.
  • Any history of hypersensitivity to fluoxetine.

研究组 & 干预措施

Fluoxetine Hydrochloride

Experimental

Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories Limited

干预措施: Fluoxetine Hydrochloride (Drug)

Prozac ® weekly

Active Comparator

Prozac ® weekly 90 mg delayed release capsules of Eli Lilly and company

干预措施: Fluoxetine Hydrochloride (Drug)

结局指标

主要结局

Bioequivalence based on Cmax and AUC parameters

时间窗: 8 months

次要结局

未报告次要终点

研究者

申办方类型
Industry

研究点 (1)

Loading locations...

相似试验